CGEM Cullinan Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1789972 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY6.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-55.5%
ROA-50.4%
ROIC (approx.)-63.9%
Asset turnover—
Leverage & solvency
Liabilities / assets12.8%
Debt / equity0.00x
Current ratio7.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $0 | $18.94M |
| R&D expense | $187.40M | $142.90M | $148.16M | $91.95M | $57.75M |
| SG&A expense | $54.25M | $54.02M | $42.49M | $40.19M | $29.15M |
| Operating income | -$241.65M | -$196.92M | -$191.09M | $144.65M | -$67.95M |
| Pretax income | -$219.88M | -$167.46M | -$169.22M | $151.32M | -$67.48M |
| Income tax | $0 | $117,000 | -$14.12M | $42.12M | $0 |
| Net income | -$219.88M | -$167.38M | -$153.16M | $111.21M | -$65.57M |
| EBITDA | -$241.34M | -$196.61M | -$190.78M | $144.74M | -$67.90M |
| EPS (basic) | — | — | -3.69 | 2.46 | -1.52 |
| EPS (diluted) | — | — | -3.69 | 2.38 | -1.52 |
| Weighted avg. shares (diluted) | — | — | 41.55M | 46.64M | 43.08M |
| Balance sheet | |||||
| Cash & equivalents | $88.33M | $83.00M | $98.43M | $156.15M | $59.77M |
| Short-term investments | $289.56M | $315.97M | $368.63M | $311.14M | $230.69M |
| Current assets | $386.76M | $414.67M | $480.19M | $474.47M | $296.56M |
| PP&E, net | $421,000 | $683,000 | $989,000 | $1.17M | $77,000 |
| Total assets | $448.37M | $621.82M | $484.18M | $561.12M | $437.19M |
| Current liabilities | $37.74M | $30.65M | $28.14M | $22.50M | $11.75M |
| Total liabilities | $39.64M | $31.50M | $30.29M | $26.09M | $11.81M |
| Shareholders' equity | $408.73M | $590.33M | $453.70M | $535.03M | $424.97M |
| Shares outstanding | 60.24M | 58.51M | 42.90M | 45.80M | 44.29M |
| Cash flow statement | |||||
| Operating cash flow | -$175.75M | -$145.30M | -$134.28M | -$126.66M | -$43.43M |
| Capital expenditure | $49,000 | $0 | $208,000 | $1.13M | $0 |
| Free cash flow | -$175.80M | -$145.30M | -$134.48M | -$127.80M | -$43.43M |
| Investing cash flow | $179.99M | -$136.31M | $35.81M | $248.97M | -$333.77M |
| Financing cash flow | $1.09M | $266.19M | $40.75M | -$25.93M | $268.78M |
| Depreciation & amortization | $311,000 | $306,000 | $310,000 | $93,000 | $53,000 |
| Stock-based compensation | $36.04M | $37.82M | $30.44M | $27.96M | $24.38M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.